NOV 07, 2018 8:47 AM PST

Zebrafish Bacterial Gut Protein Delays Death by Septic Shock

WRITTEN BY: Nouran Amin

At the University of Oregon, researchers identified a novel anti-inflammatory protein that is secreted by the common gut bacterium in zebrafish.

The protein, Aeromonas immune modulator (AimA), was found to reduce inflammation in the gut and delay death by septic shock. AimA is a mutual beneficial protein for both the bacterium and their host, the zebrafish.

Image Credit:

"We used zebrafish as a model host because we could perform many tests and search in an unbiased way for new anti-inflammatory factors,” explains study co-author and professor of biology Karen Guillemin.

Results of the study were published in the journal eLife which sheds light on the role of resident microbes and the levels of an inflammatory response.

"One of the major questions about how we coexist with our microbial inhabitants is why we don't have a massive inflammatory response to the trillions of the bacteria inhabiting our guts," says Guillemin. "We set out to test whether gut bacteria actively secrete factors that prevent an excessive inflammatory response, which would be detrimental not only to the host but also to the bacterial residents.”

Using protein crystallography, researchers were able to identify the structural similarity of AimA to a class of proteins called lipocalins, which include other proteins that modulate inflammation in humans.

"That structural similarity suggested to us that the bacterial protein may function like the human protein" Guillemin said. "In particular, rather than doing something specific to counteract inflammation caused by one kind of bacteria, maybe it was doing something more generally to temper the host's immune response."

Researchers discovered that the AimA protein reduced inflammation but also induced a lethal inflammatory response, known as septic shock. However, what they also found was AimA could counteract the sepsis extending the lifespan of the zebrafish.

"The bacteria were experiencing this inflammation, which is detrimental to them," says Guillemin. "Inflammation involves the production of antimicrobial compounds like reactive oxygen species that are designed for clearing bacteria, so, now, a beneficial bacterium is going to be at a disadvantage if it's experiencing too much of this inflammatory response."

Watch this short video below to learn more about inflammation:

"Most studies of beneficial microbes have focused exclusively on the benefits to the host and have tended to find very generic microbial molecules, such as metabolic byproducts, as the mediators," she said. "The discovery of AimA is exciting because it is a very specific specialized product that a mutualist is making for maintaining that mutualism. I suspect there are many more of these mutualism factors to be found."


Findings of the research study are pertinent to drug discovery with applications of treating human diseases associated with excessive inflammation such as intestinal inflammation, including inflammatory bowel diseases, or used in the prevention of chronic inflammation associated with metabolic syndrome and sepsis.

Source: ScienceDaily, eLife


About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 11, 2019
NOV 11, 2019
The Women Who Can Smell Without Olfactory Bulbs
Until now, it has been commonly accepted that our sense of smell depends on the transmission of olfactory information from the nose to the olfactory bulb i...
NOV 19, 2019
Drug Discovery & Development
NOV 19, 2019
Antibiotics from the Sea?
Many of the clinically relevant antibiotics are sourced from natural substances, produced by bacteria. But because of the growing threat of antibiotic resi...
DEC 22, 2019
Genetics & Genomics
DEC 22, 2019
New Gene Therapy Uses Exosomes to Reverse Disease
Researchers at Ohio State University have developed a new gene therapy that makes use of exosomes, fluid sacs released in cells, to carry therapeutic tools...
DEC 23, 2019
Drug Discovery & Development
DEC 23, 2019
FDA Approves New Schizophrenic Drug
The US Food and Drug Administration (FDA) has approved an atypical antipsychotic Caplyta (lumateperone; Intra-Cellular Therapies) for the treating schizoph...
JAN 15, 2020
Drug Discovery & Development
JAN 15, 2020
Treating Malaria: Molecular Understanding of Drug Interactions
Crystallization is a process central to drug development that despite centuries of facilitating a particular method, chemists are still learning how to gra...
JAN 23, 2020
Cell & Molecular Biology
JAN 23, 2020
Scientists Engineer Venom-Producing Organoids
Snake venom is also a source of therapeutics, and a potential source of new medicines....
Loading Comments...